Key Highlights
- Gilead Sciences has committed to purchasing German biotech firm Tubulis GmbH through a deal valued at up to $5 billion, including a $3.15 billion initial payment.
- This acquisition strengthens Gilead’s antibody-drug conjugate (ADC) portfolio, focusing on treatments for ovarian cancer and non-small cell lung cancer.
- RBC Capital Markets increased its GILD price target from $118 to $123 while maintaining a Sector Perform rating.
- RBC analysts project Yeztugo could surpass Q1 consensus estimates by $180 million, though they note risks related to compliance rates and market penetration.
- Multiple Wall Street firms including Cantor Fitzgerald, UBS, and Deutsche Bank maintain bullish positions with price targets reaching $155.
Gilead Sciences (GILD) has announced plans to acquire Munich-headquartered Tubulis GmbH through an all-cash transaction valued at up to $5 billion.
Gilead Sciences agrees to buy private German biotech Tubulis in a deal worth up to $5 billion as it looks to boost its portfolio in a hot new area of cancer drug development, sources say https://t.co/KRZYp5EQv0
— Bloomberg (@business) April 7, 2026
The acquisition structure includes an immediate payment of $3.15 billion, with an additional $1.85 billion contingent upon achieving specific development and commercial milestones. Gilead will finance this transaction through existing cash reserves and senior unsecured notes, anticipating completion during Q2 2026.
Tubulis specializes in antibody-drug conjugates, an innovative cancer therapy approach that delivers chemotherapy agents directly to malignant cells while minimizing impact on healthy tissue. The company’s primary candidate, TUB-040, is currently undergoing Phase 1b/2 clinical evaluation for platinum-resistant ovarian cancer and non-small cell lung cancer.
CEO Daniel O’Day characterized the enhanced pipeline as potentially representing the most robust and varied collection in company history.
Shares declined approximately 1.37% following Tuesday’s announcement, reflecting a common market response to significant upfront capital commitments.
RBC Capital Markets Elevates Target While Maintaining Neutral Rating
RBC Capital Markets adjusted its GILD price target upward to $123 from $118 while preserving a Sector Perform rating — effectively a neutral stance. The firm highlighted encouraging early momentum for Yeztugo, a newer Gilead therapy, based on third-party prescription tracking data.
RBC’s analysis suggests Yeztugo could exceed Q1 consensus projections by approximately $180 million, compared to the $141 million Street estimate. This represents a substantial variance should the forecast prove accurate.
The firm also expressed measured caution regarding certain aspects. RBC observed that buy-side projections for full-year 2026 appear to already incorporate expectations around $1 billion. Should compliance metrics or market penetration fail to sustain current trajectories, those optimistic peak revenue forecasts may require downward revision.
Current compliance tracking sits around 70% according to RBC’s research — a respectable figure, though one offering limited cushion for deterioration.
RBC also identified potential seasonal headwinds in other segments. HIV revenue projections stand at $4.8 billion compared to the $4.9 billion consensus, while Veklury revenue estimates reach $141 million versus Street expectations of $216 million.
Gilead’s Q1 earnings report is scheduled for April 23.
Wall Street Analysts Maintain Optimistic Outlook
Several firms continue expressing confidence in Gilead’s prospects. Cantor Fitzgerald reaffirmed an Overweight rating alongside a $155 price target, emphasizing robust prescription momentum throughout Gilead’s HIV product portfolio.
UBS also sustained a Buy rating, highlighting a 56% month-over-month increase in Yeztugo sales during February. Deutsche Bank maintained its Buy rating and $155 target, forecasting Q1 Yeztugo sales around $118 million.
In a related development, Gilead extended the deadline for its Arcellx common stock tender offer to April 24, 2026. The proposal provides $115.00 per share in cash, supplemented by contingent value rights linked to future commercial milestones.
With Q1 financial results approaching on April 23, investor attention will focus on whether Yeztugo’s promising early momentum produces tangible revenue outperformance.
